Skip to main content
Top
Published in: Clinical Rheumatology 1/2009

01-06-2009 | Case Report

A case of systemic lupus erythematosus with extensive brain stem involvement

Authors: Susheel Kumar, Navneet Sharma, Aman Sharma, Sushil Mahi, Ashish Bhalla, Subhash Varma

Published in: Clinical Rheumatology | Special Issue 1/2009

Login to get access

Abstract

Systemic lupus erythematosus (SLE) is a multisystem, autoimmune connective tissue disorder. Neuropsychiatric SLE (NPSLE) has varied clinical and radiological manifestations. Clinical manifestations range from subtle abnormalities of neurocognitive functions and mood changes to overt psychiatric or neurological manifestations such as seizures, stroke, and psychosis. Magnetic resonance imaging (MRI) may show various types of abnormalities. Cerebral white matter lesions are most common (60–86%). Here, we are discussing a young female who presented with alteration of sensorium and right-sided hemiparesis, and MRI of the brain showed extensive involvement of brainstem in the form of possible demyelination.
Literature
1.
go back to reference American College of Rheumatology (1999) Nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608CrossRef American College of Rheumatology (1999) Nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42:599–608CrossRef
2.
go back to reference Mok CC, To CH, Mak A (2006) Neuropsychiatric damage in southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 85:221–228CrossRef Mok CC, To CH, Mak A (2006) Neuropsychiatric damage in southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 85:221–228CrossRef
3.
go back to reference Sibbitt WL, Sibbitt RR, Brooks WM (1999) Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 42:2026–2038PubMedCrossRef Sibbitt WL, Sibbitt RR, Brooks WM (1999) Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 42:2026–2038PubMedCrossRef
4.
go back to reference Lalani TA, Kanne JP, Hatfield GA et al (2004) Imaging findings in systemic lupus erythematosus. Radiographics 24:1069–1086PubMedCrossRef Lalani TA, Kanne JP, Hatfield GA et al (2004) Imaging findings in systemic lupus erythematosus. Radiographics 24:1069–1086PubMedCrossRef
5.
go back to reference Jennings JE, Sundgren PC, Attwood J et al (2004) Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 46:15–21PubMedCrossRef Jennings JE, Sundgren PC, Attwood J et al (2004) Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 46:15–21PubMedCrossRef
6.
go back to reference Sailer M, Burchert W, Ehrenheim C et al (1997) Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 244:186–193PubMedCrossRef Sailer M, Burchert W, Ehrenheim C et al (1997) Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 244:186–193PubMedCrossRef
7.
go back to reference Sabet A, Sibbitt WL Jr, Stidley CA et al (1998) Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 29:2254–2260PubMed Sabet A, Sibbitt WL Jr, Stidley CA et al (1998) Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 29:2254–2260PubMed
8.
go back to reference Provenzale JM, Barboriak DP, Allen NB et al (1996) Patients with antiphospholipid antibodies: CT and MR findings of the brain. AJR Am J Roentgenol 167:1573–1578PubMed Provenzale JM, Barboriak DP, Allen NB et al (1996) Patients with antiphospholipid antibodies: CT and MR findings of the brain. AJR Am J Roentgenol 167:1573–1578PubMed
9.
go back to reference Ishikawa O, Ohnishi K, Miyachi Y et al (1994) Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging: relationship to anticardiolipin antibody. J Rheumatol 21:87–90PubMed Ishikawa O, Ohnishi K, Miyachi Y et al (1994) Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging: relationship to anticardiolipin antibody. J Rheumatol 21:87–90PubMed
10.
go back to reference Trevisani VF et al (2000) Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus (Cochrane review). Cochrane Database Syst Rev 3:CD00265 Trevisani VF et al (2000) Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus (Cochrane review). Cochrane Database Syst Rev 3:CD00265
11.
go back to reference Leung FK, Fortin PR (2003) Intravenous cyclophosphamide and high dose corticosteroids improve MRI lesions in demyelinating syndrome in systemic lupus erythematosus. J Rheumatol 30:1871–1873PubMed Leung FK, Fortin PR (2003) Intravenous cyclophosphamide and high dose corticosteroids improve MRI lesions in demyelinating syndrome in systemic lupus erythematosus. J Rheumatol 30:1871–1873PubMed
12.
go back to reference Khamashta MA, Cuadrado MJ, Mujic F et al (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997PubMedCrossRef Khamashta MA, Cuadrado MJ, Mujic F et al (1995) The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332:993–997PubMedCrossRef
Metadata
Title
A case of systemic lupus erythematosus with extensive brain stem involvement
Authors
Susheel Kumar
Navneet Sharma
Aman Sharma
Sushil Mahi
Ashish Bhalla
Subhash Varma
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue Special Issue 1/2009
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-009-1171-6

Other articles of this Special Issue 1/2009

Clinical Rheumatology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.